Aisling Capital Management LP's Q4 2025 13F: 1 new position, 2 exits
Form 13F-HR for the quarter ended Dec 31, 2025 · filed Feb 10, 2026 · 13 reported positions · accession 0001766721-26-000001
What changed this quarter
| Activity | Security | Weight before | Weight now | Change | Shares | Shares % |
|---|---|---|---|---|---|---|
| Reduced | BridgeBio Pharma Inc. (BBIO) (BBIO) | 69.3% | 81.3% | +12.0 pts | −1M sh | −16% |
| Exited | Verona Pharma plc (VRNA) (VRNA) | 14.4% | — | −14.4 pts | −615K sh | −100% |
| Exited | Nuvation Bio Inc. (NUVB) (NUVB) | 2.4% | — | −2.4 pts | −2.96M sh | −100% |
| New | Urogen Pharma Ltd. (URGN) (URGN) | — | 0.5% | +0.5 pts | +108K sh | new |
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 99.6% of the equity book
Changes in the top 10 this quarter: CALC entered · URGN entered · VRNA left · NUVB left
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | BridgeBio Pharma Inc. (BBIO) (BBIO) | 69.3% | 81.3% | |
| 2 | Syndax Pharmaceuticals, Inc. (SNDX) (SNDX) | 4.4% | 5.8% | |
| 3 | Monte Rosa Therapeutics Inc (GLUE) (GLUE) | 2.4% | 4.8% | |
| 4 | Bicara Therapeutics Inc. (BCAX) (BCAX) | 2.0% | 2.0% | |
| 5 | Compass Pathways Plc (CMPS) (CMPS) | 1.5% | 1.7% | |
| 6 | BridgeBio Oncology Therapeutics (BBOT) (BBOT) | 1.4% | 1.5% | |
| 7 | CalciMedica, Inc. (CALC) (CALC) | 0.4% | 0.7% | Entered the top 10 |
| 8 | Scholar Rock Holding Corporation (SRRK) (SRRK) | 0.6% | 0.7% | |
| 9 | Biomea Fusion Inc (BMEA) (BMEA) | 0.9% | 0.5% | |
| 10 | Urogen Pharma Ltd. (URGN) (URGN) | 0.0% | 0.5% | Entered the top 10 |
| — | Verona Pharma plc (VRNA) (VRNA) | 14.4% | 0.0% | Left the top 10 |
| — | Nuvation Bio Inc. (NUVB) (NUVB) | 2.4% | 0.0% | Left the top 10 |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).